Stock Movement | InnoSilicon once surged 15% after reaching a cooperation agreement with Lili Dai

SighingCashier · 2026-03-30T02:18:26+00:00

Enjie Intelligent and Eli Lilly reach a drug collaboration agreement worth up to $2.75 billion, with the stock price rising against the market trend, reaching a maximum increase of 14.9%. This collaboration will combine AI-driven drug development capabilities to accelerate the discovery and development of new therapies, with Eli Lilly obtaining exclusive global licensing rights.

SighingCashier

2026-03-30 02:18:26

Abstract generation in progress

AI drug development company Insilico Medicine (03696) has reached a collaboration with the American giant Eli Lilly worth up to $2.75 billion, with its stock price rising against the trend, peaking at a 14.9% increase to reach $65.75.

As of 10:04 AM, it was reported at $62, up 8.4%, with a transaction volume of $329 million.

Insilico Medicine announced last night that it has reached a licensing and drug development collaboration agreement with Eli Lilly, under which Insilico Medicine will be eligible to receive an upfront payment of $115 million (approximately HK$897 million), with the total transaction value potentially reaching about $2.75 billion (approximately HK$21.45 billion).

According to the cooperation agreement, both parties will utilize Insilico Medicine’s AI pharmaceutical capabilities to accelerate the discovery and development of new therapies across multiple therapeutic areas. Eli Lilly will obtain a global exclusive license for the development, production, and commercialization of new oral therapies targeting specific indications, which are currently in the preclinical development stage and have the potential to become “best-in-class.”

Additionally, Insilico Medicine’s Pharma.AI platform capabilities will be combined with Eli Lilly’s deep expertise in research and development, and multiple R&D collaborations will be initiated around targets selected by Eli Lilly in the future.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.